Foghorn Therapeutics (FHTX) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Foghorn Therapeutics (FHTX) over the past year, gaining 36.0% versus a loss of 55.8%. Over five years, VTVT leads with a -48.8% price change compared with -83.1% for FHTX. vTv Therapeutics is the larger company by market cap ($118.9 million vs $118.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | VTVT |
|---|---|---|
| Share price | $1.99 | $30.08 |
| Market cap | $118.18M | $118.93M |
| 1-day change | -4.78% | -3.00% |
| YTD return | -63.15% | -24.78% |
| 1-year return | -55.78% | +35.99% |
| 5-year return | -83.12% | -48.84% |
| EPS (TTM) | $-0.98 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $44.00 |
| 52-week low | $1.79 | $19.50 |
| Distance from 52-week high | -73.85% | -31.64% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +201.51% | +81.88% |
| Average volume | 616.68K | 67.89K |
| Shares outstanding | 59.39M | 3.95M |
| Employees | 106 | 26 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed FHTX by 91.8 percentage points over the past year.
- The two companies sit in different sectors: Foghorn Therapeutics in Health Care and vTv Therapeutics in Healthcare.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Healthcare · Biotechnology · 26 employees
FHTX vs VTVT FAQ
Which is bigger, Foghorn Therapeutics or vTv Therapeutics?
vTv Therapeutics (VTVT) is larger, with a market capitalization of $118.93M compared with $118.18M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or VTVT?
VTVT returned +35.99% over the past 12 months, compared with -55.78% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and vTv Therapeutics in the same industry?
No. Foghorn Therapeutics is in the Health Care sector, while vTv Therapeutics is in Healthcare.